OXYTOCIN 20 USP UNITS IN DEXTROSE 5%
Clinical safety rating
cautionComprehensive clinical and safety monograph for OXYTOCIN 20 USP UNITS IN DEXTROSE 5% (OXYTOCIN 20 USP UNITS IN DEXTROSE 5%).
Comprehensive clinical and safety monograph for OXYTOCIN 20 USP UNITS IN DEXTROSE 5% (OXYTOCIN 20 USP UNITS IN DEXTROSE 5%).
Induction of labor at termAugmentation of labor in hypotonic uterine inertiaPostpartum hemorrhage prevention and treatmentIncomplete abortion (off-label)Milk ejection reflex stimulation (off-label)
Oxytocin is a nonapeptide hormone that acts on oxytocin receptors (OXTR) in uterine myometrium and mammary gland epithelium, leading to Gq/11-coupled phospholipase C activation, increasing intracellular Ca2+ and promoting uterine smooth muscle contractions. It also stimulates milk ejection by contracting myoepithelial cells.
| Metabolism | Oxytocin is rapidly metabolized in the liver and kidneys by aminopeptidases (oxytocinase). Small amounts are also metabolized in the mammary gland and other tissues. Half-life is approximately 3-5 minutes. |
| Excretion | Primarily renal (>99% as intact peptide, small amount as metabolites). Biliary/fecal excretion negligible. |
| Half-life | Terminal elimination half-life: 1–6 minutes (IV), with a slower second phase of 12–20 minutes. Clinical context: Rapid clearance necessitates continuous IV infusion for sustained uterotonic effect. |
| Protein binding | 30% (primarily albumin; no specific binding protein identified). |
| Volume of Distribution | 0.1–0.3 L/kg (low Vd, reflecting limited extravascular distribution, primarily in extracellular fluid). |
| Bioavailability | Oral: <1% (degraded by gastrointestinal peptidases). IM: 70–80%. Intranasal: 10–20%. IV: 100%. |
| Onset of Action | IV: ≤1 minute. IM: 3–5 minutes. Intranasal: 5–10 minutes. |
| Duration of Action | IV: 20–60 minutes (infusion-dependent). IM: 2–3 hours. Intranasal: 2–4 hours. Note: Tachyphylaxis may reduce effect with prolonged use. |
| Molecular Weight | 1007.19 |
Initial infusion at 0.5-2 mU/min, increased by 1-2 mU/min every 15-30 min until desired uterine activity, then taper. Maximum dose typically 20 mU/min.
| Dosage form | INJECTABLE |
| Renal impairment | No specific GFR-based dose adjustment required; use with caution in severe renal impairment due to fluid overload risk from dextrose 5%. |
| Liver impairment | No specific Child-Pugh based adjustment required; oxytocin is metabolized primarily in liver, but no dose modification guidelines exist for hepatic impairment. |
| Pediatric use | Not indicated; use only for labor induction/augmentation in pregnant adolescents. No weight-based dosing for other indications. |
| Geriatric use | Not indicated in elderly; contraindicated for non-obstetric uses in postmenopausal women. No specific geriatric dose recommendations. |
| 1st trimester | Oxytocin is a natural hormone; use only for medically indicated reasons (e.g., missed abortion). No known teratogenicity, but data limited. |
| 2nd trimester | Use for induction of labor when indicated; avoid prolonged use due to risk of uterine hyperstimulation. |
| 3rd trimester | Used for induction/augmentation of labor; risk of uterine hyperstimulation, fetal distress, and water intoxication. |
Clinical note
Comprehensive clinical and safety monograph for OXYTOCIN 20 USP UNITS IN DEXTROSE 5% (OXYTOCIN 20 USP UNITS IN DEXTROSE 5%).
| Placental transfer | Oxytocin crosses the placenta minimally, but exogenous administration can stimulate uterine contractions affecting fetal oxygenation. |
| Breastfeeding | Oxytocin is rapidly metabolized in the gastrointestinal tract; not orally bioavailable. Excretion into breast milk is negligible. Use during breastfeeding is considered safe. |
| Lactation Rating | L1 |
| Teratogenic Risk | Oxytocin is not a known human teratogen. In the first trimester, exposure is primarily from endogenous oxytocin; exogenous oxytocin for induction/augmentation is given in late pregnancy. No increased risk of structural anomalies has been documented. Second and third trimester use is for labor induction/augmentation and postpartum hemorrhage; risks are related to uterine hyperstimulation, fetal distress, and neonatal jaundice, not direct teratogenicity. |
| Fetal Monitoring | Continuous electronic fetal heart rate monitoring and uterine activity monitoring (tocodynamometry) required during oxytocin infusion. Maternal vital signs, fluid balance, and signs of uterine hyperstimulation or tetanic contractions must be assessed frequently. Monitor for water intoxication (hyponatremia) due to antidiuretic effect, especially with high doses or prolonged infusion. Serum electrolytes may be checked if indicated. |
| Fertility Effects | No known adverse effects on fertility. Oxytocin is used therapeutically for induction of labor and does not impair future fertility. Endogenous oxytocin plays a role in parturition and lactation but not in ovulation or implantation. |
■ FDA Black Box Warning
Oxytocin should be used only for medical indications and not for elective induction of labor. Proper dosing and monitoring are essential to avoid uterine hyperstimulation, which can lead to fetal hypoxia, uterine rupture, or maternal death. Continuous fetal monitoring and qualified personnel must be available.
| Serious Effects |
Hypersensitivity to oxytocin or any componentSignificant cephalopelvic disproportionUnfavorable fetal presentationFetal distress where vaginal delivery is not imminentHypertonic or hyperactive uterine contractionsConditions where vaginal delivery is contraindicated (e.g., placenta previa, vasa previa, cord prolapse)
| Precautions | Uterine hyperstimulation leading to fetal distress, uterine rupture, or maternal injury, Water intoxication due to antidiuretic effect of oxytocin, especially with high doses and prolonged infusion, Fetal bradycardia and other adverse fetal effects, Monitor uterine activity, fetal heart rate, and maternal vital signs closely, Use caution in severe hypertension, cardiovascular disease, or grand multiparity |
| Food/Dietary | No specific food interactions. Maintain hydration but avoid large meals during labor due to risk of aspiration. Clear liquids may be allowed per institutional protocol. No other dietary restrictions. |
| Clinical Pearls | Oxytocin must be administered via IV infusion with a controlled infusion device. Titrate dose to achieve adequate uterine contractions (≤5 contractions per 10 minutes). Monitor for tachysystole (contractions >5 per 10 minutes) and fetal heart rate changes. Discontinue immediately if signs of uterine hyperstimulation or fetal distress occur. Have terbutaline or magnesium sulfate available for tocolysis. Do not use in cases of significant cephalopelvic disproportion or non-reassuring fetal status. Administer with caution in patients with multiple gestations or overdistended uterus. |
| Patient Advice | This medication is used to start or strengthen labor contractions or to control bleeding after delivery. · Report any contractions that feel overly frequent or prolonged, or if you have difficulty breathing. · You will have continuous monitoring of your contractions and your baby's heart rate during infusion. · Notify your nurse immediately if you experience headache, blurred vision, or chest pain. · This medication is given intravenously and requires careful adjustment by your healthcare team. |
Loading safety data…